Jon K Bjerregaard

Summary

Affiliation: Odense University Hospital
Country: Denmark

Publications

  1. ncbi Characteristics, therapy and outcome in an unselected and prospectively registered cohort of pancreatic cancer patients
    J K Bjerregaard
    Department of Oncology, Odense University Hospital, Denmark
    Eur J Cancer 49:98-105. 2013
  2. ncbi Prognostic factors for survival and resection in patients with initial nonresectable locally advanced pancreatic cancer treated with chemoradiotherapy
    Jon K Bjerregaard
    Department of Oncology, Odense University Hospital, Odense, Denmark
    Int J Radiat Oncol Biol Phys 83:909-15. 2012
  3. ncbi Long-term results of concurrent radiotherapy and UFT in patients with locally advanced pancreatic cancer
    Jon K Bjerregaard
    Department of Oncology, Odense University Hospital, Sdr Boulevard 29, Odense C, Denmark
    Radiother Oncol 92:226-30. 2009
  4. ncbi Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum
    Katrine R Schoennemann
    Department of Oncology, Odense University Hospital, Sdr Boulevard 29, 5000, Odense C, Denmark
    Gastric Cancer 14:219-25. 2011
  5. ncbi Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer
    Finn Ole Larsen
    Department of Oncology, Herlev Hospital, University of Copenhagen, Denmark
    Acta Oncol 50:574-7. 2011

Collaborators

Detail Information

Publications5

  1. ncbi Characteristics, therapy and outcome in an unselected and prospectively registered cohort of pancreatic cancer patients
    J K Bjerregaard
    Department of Oncology, Odense University Hospital, Denmark
    Eur J Cancer 49:98-105. 2013
    ..Therefore, we investigated patient baseline characteristics, therapy choices and survival in a complete cohort of patients with PC...
  2. ncbi Prognostic factors for survival and resection in patients with initial nonresectable locally advanced pancreatic cancer treated with chemoradiotherapy
    Jon K Bjerregaard
    Department of Oncology, Odense University Hospital, Odense, Denmark
    Int J Radiat Oncol Biol Phys 83:909-15. 2012
    ..We describe the results in 178 patients treated from 2001 to 2010 and have developed a prognostic model for both survival and the possibility of a subsequent resection in these patients...
  3. ncbi Long-term results of concurrent radiotherapy and UFT in patients with locally advanced pancreatic cancer
    Jon K Bjerregaard
    Department of Oncology, Odense University Hospital, Sdr Boulevard 29, Odense C, Denmark
    Radiother Oncol 92:226-30. 2009
    ..Treatment options range from palliative chemotherapy to chemoradiotherapy (CRT). Several studies have shown that a number of patients become resectable after complementary treatment prior to surgery...
  4. ncbi Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum
    Katrine R Schoennemann
    Department of Oncology, Odense University Hospital, Sdr Boulevard 29, 5000, Odense C, Denmark
    Gastric Cancer 14:219-25. 2011
    ..Inspired by therapy in metastatic colorectal cancer, a combination of cetuximab and irinotecan (Cetiri) was chosen for second-line therapy in GEC patients. We report our experience with Cetiri as second-line therapy in patients with GEC...
  5. ncbi Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer
    Finn Ole Larsen
    Department of Oncology, Herlev Hospital, University of Copenhagen, Denmark
    Acta Oncol 50:574-7. 2011
    ..The efficacy and safety of concurrent administration of irinotecan with the two monoclonal antibodies cetuximab and bevacizumab as fourth line therapy in heavily pretreated patients with metastatic colorectal cancer were evaluated...